Delving into the Latest Updates on Shanghai Helioson Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Immune System Diseases

Small molecule drug

Degradable Molecular Glue

Proteolysis-targeting chimeras (PROTAC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	12
Immune System Diseases	7
Endocrinology and Metabolic Disease	4
Nervous System Diseases	3
Hemic and Lymphatic Diseases	3
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Degradable Molecular Glue	3
Proteolysis-targeting chimeras (PROTAC)	3
Molecular glue	3
Degrader-antibody conjugates	1

Top 5 Target	Count

BTK(Tyrosine-protein kinase BTK)	2
IKZF1 x IKZF3	2
PDE3A x SLFN12	2
GSPT1(G1 to S phase transition 1)	1
AR(Androgen Receptor)	1

主要目的：评估 HP-001 胶囊联合地塞米松在复发难治多发性骨髓瘤（MM）中的安全性、耐受性。次要目的：评估 HP-001 胶囊联合地塞米松在复发难治 MM 中的药代动力学（PK）特征。评估 HP-001 胶囊联合地塞米松在复发难治 MM 中的有效性。探索目的：评估与抗肿瘤活性可能有关的药效学（PD）生物标志物。

[Translation]

Primary Objective: To evaluate the safety and tolerability of HP-001 capsules combined with dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Secondary Objective: To evaluate the pharmacokinetic (PK) characteristics of HP-001 capsules combined with dexamethasone in patients with relapsed or refractory MM. To evaluate the efficacy of HP-001 capsules combined with dexamethasone in patients with relapsed or refractory MM. Exploratory Objective: To evaluate pharmacodynamic (PD) biomarkers potentially associated with antitumor activity.

Start Date-

Sponsor / Collaborator

Shanghai Helioson Pharmaceutical Co., Ltd.

100 Clinical Results associated with Shanghai Helioson Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Helioson Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Helioson Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Helioson Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

11

2

Preclinical

Phase 2

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HP-001 ( IKZF1 x IKZF3 )	Hematologic Neoplasms More	IND Approval
CY-002 ( PDE3A x SLFN12 )	Hepatocellular Carcinoma More	Preclinical
HP-002 ( BTK )	Hematologic Neoplasms More	Preclinical
WO2025162210 ( BTK )Patent Mining	Hemic and Lymphatic Diseases More	Discovery
CN119684303 ( AR )Patent Mining	Puberty, Precocious More	Discovery